

Longitudinal Patient Data - France

First published: 01/02/2024

Last updated: 17/10/2024

Data source

Human

Primary care medical records

Administrative details

Administrative details

Data source ID

1111149

Data source acronym

LPD FRA

Data holder

[IQVIA](#)

Data source type

Primary care medical records

Main financial support

Funding by own institution

Funding from industry or contract research

Care setting

Primary care – GP, community pharmacist level

Primary care – specialist level (e.g. paediatricians)

Data source qualification

If the data source has successfully undergone a formal qualification process (e.g., from the EMA, ISO or other certifications), this should be described.

No

Data source website

<https://www.iqvia.com/solutions/real-world-evidence/real-world-data-and-insights>

Contact details

Sarah Seager sarah.seager@iqvia.com



sarah.seager@iqvia.com

Data source regions and languages

Data source countries

France

Data source languages

French

Data source establishment

Data source established

15/06/1991

Data source time span

First collection: 01/01/2012

The date when data started to be collected or extracted.

Publications

Data source publications

[Analysis of Dual Combination Therapies Used in Treatment of Hypertension in a Multinational Cohort. JAMA Netw Open. 2022;5\(3\):e223877. doi:10.1001/jamanetworkopen.2022.3877.](#)

[Rates of Antipsychotic Drug Prescribing Among People Living With Dementia During the COVID-19 Pandemic. AMA Psychiatry. 2023 Mar 1;80\(3\):211-219.](#)

[Background rates of five thrombosis with thrombocytopenia syndromes of special interest for COVID -19 vaccine safety surveillance: incidence between 2017 and 2019 and patient profiles from 38.6 million people in six European countries. Pharmacoepidemiology and Drug Safety \(2022\). 10.1002/pds.5419.](#)

Studies

List of studies that have been conducted using the data source

[Drug Utilisation Study for Olodaterol](#)

[Drug Utilization Study of Thiocolchicoside \(TCC\) containing medicinal products for systemic use in France and Italy: an electronic medical records databases study](#)

Drug Utilisation Study of conjugated oestrogens/bazedoxifene (CE/BZA) in the European Union (EU)

Study of exposure and use patterns of alternatives to ranitidine-containing medicines in patients treated with ranitidine (Ranitidine)

Drug utilization of Intrarosa (6.5 mg prasterone pessary) in European Countries (ERC-243)

A Retrospective Cohort Study for Estimating Incidence Rates of Infusion Site Events for ABBV-951 for the Treatment of Advanced Parkinson's Disease

An Observational Study Assessing the Long-term Risk of Non-Melanoma Skin Cancer (NMSC) Among New Users of Opzelura™ (Ruxolitinib) Cream in a Vitiligo Patient Population: Post-Authorization Safety Study (PASS)

COPD, Bronchiectasis and Asthma Longitudinal Trends

Data elements collected

The data source contains the following information

Disease information

Does the data source collect information with a focus on a specific disease? This might be a patient registry or other similar initiatives.

No

Rare diseases

Are rare diseases captured? In the European Union a rare disease is one that affects no more than 5 people in 10,000.

No

Pregnancy and/or neonates

Does the data source collect information on pregnant women and/or neonatal subpopulation (under 28 days of age)?

Yes

Hospital admission and/or discharge

No

ICU admission

Is information on intensive care unit admission available?

No

Cause of death

Captured

Cause of death vocabulary

Not coded (Free text)

Prescriptions of medicines

Captured

Prescriptions vocabulary

RxNorm

Dispensing of medicines

Captured

Dispensing vocabulary

other

RxNorm

Dispensing vocabulary, other

CVX

Advanced therapy medicinal products (ATMP)

Is information on advanced therapy medicinal products included? A medicinal product for human use that is either a gene therapy medicinal product, a somatic cell therapy product or a tissue engineered products as defined in Regulation (EC) No 1394/2007 [Reg (EC) No 1394/2007 Art 1(1)].

No

Contraception

Is information on the use of any type of contraception (oral, injectable, devices etc.) available?

Yes

Indication for use

Does the data source capture information on the therapeutic indication for the use of medicinal products?

Captured

Indication vocabulary

SNOMED

Medical devices

Is information on medicinal devices (e.g., pens, syringes, inhalers) available?

No

Administration of vaccines

No

Procedures

Does the data source capture information on procedures (e.g., diagnostic tests, therapeutic, surgical interventions)?

Captured

Procedures vocabulary

SNOMED

Healthcare provider

Is information on the person providing healthcare (e.g., physician, pharmacist, specialist) available? The healthcare provider refers to individual health professionals or a health facility organisation licensed to provide health care diagnosis and treatment services including medication, surgery and medical devices.

Yes

Clinical measurements

Is information on clinical measurements (e.g., BMI, blood pressure, height) available?

Yes

Genetic data

Are data related to genotyping, genome sequencing available?

Not Captured

Biomarker data

Does the data source capture biomarker information? The term “biomarker” refers to a broad subcategory of medical signs (objective indications of medical state observed from outside the patient), which can be measured accurately and reproducibly. For example, haematological assays, infectious disease markers or metabolomic biomarkers.

Captured

Biomarker data vocabulary

Other

Biomarker vocabulary, other

LOINC,SNOMED

Patient-reported outcomes

Is information on patient-reported outcomes (e.g., quality of life) available?

No

Patient-generated data

Is patient-generated information (e.g., from wearable devices) available?

Yes

Units of healthcare utilisation

Are units of healthcare utilisation (e.g., number of visits to GP per year, number of hospital days) available or can they be derived? Units of healthcare utilisation refer to the quantification of the use of services for the purpose of preventing or curing health problems.

Yes

Unique identifier for persons

Are patients uniquely identified in the data source?

Yes

Diagnostic codes

Captured

Diagnosis / medical event vocabulary

SNOMED

Medicinal product information

Captured

Medicinal product information collected

Active ingredient(s)

Brand name

Package size

Route of administration

Strength

Medicinal product vocabulary

RxNorm

Quality of life measurements

Captured

Quality of life measurements vocabulary

Not coded (Free text)

Lifestyle factors

Captured

Lifestyle factors

Alcohol use

Other

Tobacco use

Sociodemographic information

Captured

Sociodemographic information collected

Gender

Marital status

Other

Pharmaceutical copayment

Quantitative descriptors

Population Qualitative Data

Population age groups

Paediatric Population (< 18 years)

Children (2 to < 12 years)

Adolescents (12 to < 18 years)

Adults (18 to < 46 years)

Adults (46 to < 65 years)

Elderly (\geq 65 years)

Adults (65 to < 75 years)

Adults (75 to < 85 years)

Adults (85 years and over)

Estimated percentage of the population covered by the data source in the catchment area

4%

Description of the population covered by the data source in the catchment area whose data are not collected (e.g., people who are registered only for private care)

General population

Family linkage

Family linkage available in the data source permanently or can be created on an ad hoc basis

Ad hoc

Population

Population size

17600000

Active population size

3700000

Population by age group

Age group	Population size	Active population size
Paediatric Population (< 18 years)	2784513	570209
Children (2 to < 12 years)	1625765	326914
Adolescents (12 to < 18 years)	822068	182539
Adults (18 to < 46 years)	6327024	1118839
Adults (46 to < 65 years)	4376782	1000914
Elderly (\geq 65 years)	3995905	1030457
Adults (65 to < 75 years)	2027632	523641
Adults (75 to < 85 years)	1317656	352820

Age group	Population size	Active population size
Adults (85 years and over)	650617	153996

Median observation time

Median time (years) between first and last available records for unique individuals captured in the data source

177.00

Median time (years) between first and last available records for unique active individuals (alive and currently registered) captured

1083.00

Data flows and management

Access and validation

Governance details

Documents or webpages that describe the overall governance of the data source and processes and procedures for data capture and management, data quality check and validation results (governing data access or utilisation for research purposes).

<https://www.pharmacoepi.org/resources/policies/guidelines-08027/>

Biospecimen access

Are biospecimens available in the data source (e.g., tissue samples)?

No

Access to subject details

Can individual patients/practitioners/practices included in the data source be contacted?

No

Description of data collection

Anonymized patient records collected from patient management software used by GPs to document patients' clinical records

Event triggering registration

Event triggering registration of a person in the data source

Practice registration

Event triggering de-registration of a person in the data source

Death

Emigration

Loss to follow up

Practice deregistration

Event triggering creation of a record in the data source

Physician encounter

Data source linkage

Linkage

Is the data source described created by the linkage of other data sources (prelinked data source) and/or can the data source be linked to other data source on an ad-hoc basis?

No

Data management specifications that apply for the data source

Data source refresh

Quarterly

Informed consent for use of data for research

Not Required

Possibility of data validation

Can validity of the data in the data source be verified (e.g., access to original medical charts)?

No

Data source preservation

Are records preserved in the data source indefinitely?

No

Data source preservation length (years)

10 years

Approval for publication

Is an approval needed for publishing the results of a study using the data source?

No

Data source last refresh

01/12/2022

Common Data Model (CDM) mapping

CDM mapping

Has the data source been converted (ETL-ed) to a common data model?

Yes

CDM Mappings

CDM name

OMOP

CDM website

<https://www.ohdsi.org/Data-standardization/>

Data source ETL CDM version

5.3.1

Data source ETL frequency

4,00 months

Data source ETL status

Completed